Emergent Biosolutions plans $50M expansion at Baltimore facility

Emergent Biosolutions is pumping $50 million into upgrades at one of its Baltimore plants.
The biopharmaceutical firm said this month that it plans to complete the expansion of the fill/finish facility in Carroll-Camden over three years.
Gaithersburg–based Emergent Biosolutions makes vaccines and therapeutics, including an anthrax vaccine that is manufactured in Baltimore. The Carroll-Camden facility is one of multiple sites in the city, along with a manufacturing operation in Bayview that itself recently doubled in size.
The latest expansion will add to the company’s contract manufacturing operations, including a new fill line to fill vials, syringes and cartridges, as well as cold storage and office space. About 60 jobs are expected to be created.
“This $50 million investment further demonstrates our commitment to meeting and exceeding the expectations of our customers as well as to stimulating economic growth and creating jobs in Baltimore.” said BJ Hull, the company’s site head at Carroll-Camden.
The announcement came on the heels of another for the company with local implications. In May, Emergent and Baltimore-based Profectus Biosciences announced an agreement to collaborate on developing of a vaccine against the Nipah Virus. The $25 million effort is funded by the Coalition for Epidemic Preparedness Innovations. Under the deal, Profectus Biosciences will develop the treatment, and Emergent will provide technical assistance and receive a licensing option for the vaccine.